One BioMed, A*Star Collaborate to Develop POC MDx Platform, Syndromic Assays

May 30, 2017

|

NEW YORK (GenomeWeb) –One BioMed and A*Star’s Genome Institute of Singapore (GIS) said on Monday that they have established a joint laboratory to develop molecular diagnostic assays for the Asian clinical infectious disease testing market.

The joint laboratory will focus on the development and integration of initial assays for One BioMed's platform.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

One BioMed, A*Star Collaborate to Develop POC MDx Platform, Syndromic Assays

To read the full story....

Breaking News

Calciscon Raises $2.7M in Series A Round

PerkinElmer Preliminary Q1 Revenues Grow 98 Percent; FDA Issues EUA for PCR COVID-19 Test

Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay

Ethos Labs, Agena Biosciences Partner on SARS-CoV-2 Variant Identification

Danaher Expects Q1 2021 Revenue Growth Above Previous Guidance

Australian Firm AnteoTech Obtains CE Marking for COVID-19 Antigen Test, Reader

What's Popular?

Siemens Healthineers Gets CE Mark for Point-of-Care High-Sensitivity Cardiac Troponin I Test

Thermo Fisher Scientific Gets FDA EUA for High-Throughput, Automated COVID-19 Test Kit

Danaher Expects Q1 2021 Revenue Growth Above Previous Guidance

DiaSorin to Acquire Luminex for $1.8B

Ortho Clinical Diagnostics Gets Additional CE Mark for Coronavirus Antigen Test

Sponsorships